SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is facing significant downward pressure following the release of topline Phase 3 LUGANO trial results, which missed the primary endpoint in the full dataset despite key secondary endpoints showing potential for reduced treatment burden. The community is actively debating the trial's ad hoc subgroup analysis, with many investors expressing deep frustration and concern over future dilution while some analysts suggest the results still support the drug's mechanism as the company shifts focus toward upcoming LUCIA trial data.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is seeing intense volatility and social media debate following a better-than-expected earnings report, with shareholders debating the impact of recent insider selling by the CTO and an adverse court ruling regarding platform liability. While some investors are betting on a recovery driven by growth in subscription revenue and upcoming AR smartglasses, others remain deeply skeptical due to concerns over executive leadership and historical stock dilution.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors react to a significant competitive-elimination catalyst following news that rival EyePoint Pharmaceuticals' Phase III trial for Duravyu missed its primary endpoint. The community is actively discussing how this development de-risks Ocular's AXPAXLI pipeline, with high message volume and bullish sentiment as market participants weigh the potential for a buyout or accelerated market dominance.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is facing selling pressure as traders react to a BofA report highlighting off-balance-sheet financing risks and concerns over shifting product margins. Despite this volatility, the community remains divided, with bulls viewing the pullback as a buying opportunity given the company's strong AI infrastructure demand while skeptics point to technical weakness and valuation concerns.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty Industries is trending as investors react to a newly announced $300M share buyback program aimed at capitalizing on the company's strategic tungsten deposits. The community is actively discussing the move as a major vote of confidence from leadership in the face of growing Western demand for non-Chinese critical minerals.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as traders react to a volatile earnings report, which highlighted record order backlog growth despite an initial market sell-off. The community is actively debating the company's long-term valuation and future contract potential, with many investors focusing on the firm's pivot to a diversified defense and space infrastructure provider.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is capturing investor interest as it scales its modular edge data center deployments, driven by an expanding pipeline of high-density AI infrastructure contracts and strategic partnerships. The community remains closely focused on the company's ability to execute on its infrastructure projects and the potential for continued revenue growth within the high-demand edge computing sector.

Quantum Corp. engages in the manufacture of computer storage devices. It provides solutions for storing and protecting information in physical, virtual, and cloud environments. Its products and services include Myriad All-Flash File and Object, StorNext File System Unified Surveillance Platform, ActiveScale Object Storage, DXi Backup Appliances, Scalar Tape Storage, CatDV Media Asset Management, and Cloud-Based Analytics. The company was founded by Joel N. Harrison and James M. McCoy in 1980 and is headquartered in Centennial, CO.

Quantum Corp

Quantum Corp (QMCO) is seeing intense volatility as the community remains divided between those betting on an AI-driven storage turnaround and those anticipating a liquidity-fueled 'pump and dump' ahead of a pending share lock-up expiration. Traders are actively debating whether the stock's recent aggressive price action is supported by fundamental demand for data infrastructure or if it is being driven by algorithmic manipulation and artificial short-squeezes.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently trading at multi-decade lows as market participants grapple with the sustainability of national debt and persistent inflation fears despite attempts at geopolitical de-escalation. Investors are actively debating whether these levels present a generational buying opportunity for long-duration exposure or if yields will continue to climb as the bond market remains skeptical of government fiscal policy.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is gaining traction as investors monitor its expansion into distributed AI data center power through a new virtual power plant partnership with Tesla and Renew Home. While some retail traders are aggressively buying the dip following recent price volatility, others remain cautious, debating whether this strategic shift will overcome sector-wide policy headwinds and interest rate pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. We...

Exelixis (EXEL) Tops Q2 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +5.81% and -0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the...

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts...

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Arcturus Therapeutics Holdings Inc. (Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help...

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in New York: 2026 Jefferies...

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.68	--	--	N/A
Q2 '26	-$0.91	-$0.84	7.99%	BEAT
Q1 '26	-$1.01	-$0.95	5.93%	BEAT
Q4 '25	-$0.78	-$1.03	-32.58%	MISSED
Q3 '25	-$0.90	-$0.49	45.49%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings